StockNews.com Upgrades Kura Oncology (NASDAQ:KURA) to “Buy”

Kura Oncology (NASDAQ:KURA) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Friday.

A number of other analysts have also commented on the stock. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. UBS Group decreased their price objective on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday. Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a report on Thursday, February 27th. BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Stock Up 4.5 %

Shares of KURA opened at $7.70 on Friday. The business’s fifty day moving average price is $8.04 and its two-hundred day moving average price is $13.51. The firm has a market capitalization of $598.78 million, a price-to-earnings ratio of -3.26 and a beta of 0.85. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. On average, analysts predict that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Transactions at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 over the last quarter. Corporate insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC lifted its position in Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after buying an additional 3,061 shares in the last quarter. Harbor Advisors LLC acquired a new stake in shares of Kura Oncology in the fourth quarter valued at about $87,000. E Fund Management Co. Ltd. acquired a new stake in shares of Kura Oncology in the fourth quarter valued at about $90,000. Corton Capital Inc. bought a new stake in Kura Oncology during the fourth quarter worth about $99,000. Finally, Optimize Financial Inc acquired a new position in Kura Oncology during the fourth quarter valued at approximately $100,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.